- Home
- CRBP vs JHI Comparison
CRBP vs JHI Comparison
Compare CRBP & JHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- JHI
- Stock Information
- Founded
- CRBP 2009
- JHI 1971
- Country
- CRBP United States
- JHI United States
- Employees
- CRBP N/A
- JHI N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- JHI Trusts Except Educational Religious and Charitable
- Sector
- CRBP Health Care
- JHI Finance
- Exchange
- CRBP Nasdaq
- JHI Nasdaq
- Market Cap
- CRBP 110.3M
- JHI 120.3M
- IPO Year
- CRBP N/A
- JHI N/A
- Fundamental
- Price
- CRBP $8.90
- JHI $14.04
- Analyst Decision
- CRBP Strong Buy
- JHI
- Analyst Count
- CRBP 10
- JHI 0
- Target Price
- CRBP $53.56
- JHI N/A
- AVG Volume (30 Days)
- CRBP 124.3K
- JHI 29.5K
- Earning Date
- CRBP 08-05-2025
- JHI 01-01-0001
- Dividend Yield
- CRBP N/A
- JHI 6.80%
- EPS Growth
- CRBP N/A
- JHI N/A
- EPS
- CRBP N/A
- JHI 1.05
- Revenue
- CRBP N/A
- JHI N/A
- Revenue This Year
- CRBP N/A
- JHI N/A
- Revenue Next Year
- CRBP $270.04
- JHI N/A
- P/E Ratio
- CRBP N/A
- JHI $12.47
- Revenue Growth
- CRBP N/A
- JHI N/A
- 52 Week Low
- CRBP $4.64
- JHI $11.63
- 52 Week High
- CRBP $61.89
- JHI $13.40
- Technical
- Relative Strength Index (RSI)
- CRBP 53.56
- JHI 65.95
- Support Level
- CRBP $9.10
- JHI $13.99
- Resistance Level
- CRBP $9.80
- JHI $14.11
- Average True Range (ATR)
- CRBP 0.62
- JHI 0.07
- MACD
- CRBP 0.01
- JHI -0.00
- Stochastic Oscillator
- CRBP 31.45
- JHI 77.14
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.